+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of riliprubart compared to the usual treatment of intravenous immunoglobulin IVIg in adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP who are currently receiving maintenance IVIg therapy. This Phase 3 randomized study aims to understand how well riliprubart works in this group over a study duration of up to 109 weeks, including screening, treatment, and follow-up periods. Participants are randomly assigned to one of two groups one group receives riliprubart along with a placebo IVIg infusion for 24 weeks, followed by an open-label extension phase with riliprubart for another 24 weeks the other group continues IVIg treatment with a placebo riliprubart for 24 weeks, then also enters the open-label riliprubart extension. Treatments are given as intravenous or subcutaneous infusions, and dosing follows established maintenance regimens. During the study, participants will have regular assessments to monitor their response to treatment. These include measuring disability and fatigue scales, grip strength, and relapse rates from baseline through various time points up to week 109. Safety is monitored by tracking treatment-emergent adverse events and antibody development. Participants are followed closely through scheduled visits to evaluate changes in their condition and overall health status throughout the study.

Age: 18Years +All GendersPhase 3
134 locations
P

Actively Recruiting

Researchers are studying the prevention of recurrent Clostridioides difficile infection CDI in adults aged 18 and older. This Phase IIb clinical trial evaluates the safety and effectiveness of a drug called AZD5148 compared to a placebo. The trial is randomized, double-blind, and placebo-controlled, aiming to reduce the chance of CDI coming back. This study is sponsored by AstraZeneca and focuses on preventing infection recurrence in participants who have recently experienced CDI and are undergoing antibacterial treatment. Participants will be randomly assigned to receive a single dose of either AZD5148 or a placebo, given by either intramuscular injection or intravenous push as decided by the investigator. The treatment is administered once during the antibacterial therapy, which must last between 10 and 28 days. The study involves up to two visits for eligibility confirmation and dosing, followed by up to seven planned visits for monitoring. Participants will also complete an electronic diary and receive follow-up contacts weekly at first, then monthly. Participants will be closely monitored through stool sample collections, symptom tracking, and assessment of any adverse events. Researchers will evaluate the first recurrence of CDI within 91 days, duration and severity of diarrhea symptoms, hospitalizations related to CDI, and any adverse reactions to the study drug. Safety assessments continue for up to 361 days after dosing, including analysis of drug levels and immune responses. The total participation time may extend over a year to fully assess outcomes and safety.

Age: 18Years +All GendersPhase 2
117 locations